source
- Johnson & Johnson shares drop 6% after earnings meet forecasts but show weak medical device outlookJohnson & Johnson reported third‑quarter results that met Wall Street expectations and raised its 2026 financial guidance, yet the stock fell about 6% on the day. Analysts highlighted an underwhel…
- FDA proposes new framework prioritizing consistency over flexibility for rare disease drug reviewsThe FDA announced a shift in its approach to evaluating rare disease therapies, emphasizing a more uniform assessment process. Agency officials explained that the flexibility shown over the summer…